The ADOA clinical trial is supposed to commence next quarter. As stated by Eaglenebula it’s testing a different drug, so the Phase 1 safety stage can’t be skipped.
But if PYC-001, which aims to increase expression of OPA1, successfully passes Phase 1 in ADOA, it's possible to skip Phase 1 in any further indications of PYC-001 which use the same route of administration and same dose.
Rohan Hockings suggested that there are other bioenergetic diseases of retinal ganglion cells which could potentially be addressed by PYC-001. Diseases he mentioned included glaucoma, leber hereditary optic neuropathy and acute ischemic optic atrophy.
Ann: RP11 Drug Candidate Progressing to Mid-Stage Human Trials, page-12
Add PYC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
10.5¢ |
Change
0.005(5.00%) |
Mkt cap ! $489.9M | |||
| Open | High | Low | Value | Volume |
| 10.5¢ | 10.5¢ | 9.7¢ | $540.3K | 5.385M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 16 | 560735 | 10.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 10.5¢ | 719070 | 4 |
View Market Depth
| Last trade - 16.10pm 31/05/2024 (20 minute delay) ? |
|
|||||
|
Last
10.5¢ |
Change
0.005 ( 0.00 %) |
||||
| Open | High | Low | Volume | ||
| 10.3¢ | 10.5¢ | 9.6¢ | 4041814 | ||
| Last updated 15.59pm 31/05/2024 ? | |||||
| PYC (ASX) Chart |